|
KMID : 1141720200080010037
|
|
폐쇄성폐질환
2020 Volume.8 No. 1 p.37 ~ p.41
|
|
|
|
|
Lee Chang-Hoon
|
|
|
Abstract
|
|
|
|
During decades, inhaled corticosteroid (ICS) has been the principal controller treatment for patients with asthma. However, many asthma patients do not keep using ICS regularly since symptoms improve, and there are concerns about the adverse effects of long-term use of ICS. This article is aimed to elucidate if stopping ICS is possible without poorer treatment outcome. To date, there are actually no studies showing that treatment results do not deteriorate when ICS is stopped. In addition, it was also found that the administration of ICS with formoterol, a rapid-onset beta-agonist as needed, was not sufficient in terms of 'control', which is the most important treatment target for asthma. The adverse effects of ICS, including pneumonia, tuberculosis and non-tuberculous mycobacterial diseases, may be not worrisome, while ICS is also superior in terms of death, which may reflect both treatment effects and adverse effects. In conclusion, stopping ICS in asthma patients is contrary to scientific evidences.
|
|
|
KEYWORD
|
|
|
Inhaled corticosteroid (ICS), Asthma, Control, As-needed, Adverse effects, Mortality
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|